{"name":"Ming-Yuan Chen","slug":"ming-yuan-chen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Cisplatin-based induction chemotherapy","genericName":"Cisplatin-based induction chemotherapy","slug":"cisplatin-based-induction-chemotherapy","indication":"Induction chemotherapy for locally advanced head and neck cancer","status":"phase_3"},{"name":"Full course of PD-1 monoclonal antibody","genericName":"Full course of PD-1 monoclonal antibody","slug":"full-course-of-pd-1-monoclonal-antibody","indication":"Advanced or metastatic melanoma","status":"phase_3"},{"name":"Full course of PD-1blockades","genericName":"Full course of PD-1blockades","slug":"full-course-of-pd-1blockades","indication":"Metastatic melanoma","status":"phase_3"}]}],"pipeline":[{"name":"Cisplatin-based induction chemotherapy","genericName":"Cisplatin-based induction chemotherapy","slug":"cisplatin-based-induction-chemotherapy","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.","indications":["Induction chemotherapy for locally advanced head and neck cancer","Induction chemotherapy for advanced ovarian cancer","Induction chemotherapy for advanced bladder cancer","Induction chemotherapy for other solid tumors"],"catalyst":""},{"name":"Full course of PD-1 monoclonal antibody","genericName":"Full course of PD-1 monoclonal antibody","slug":"full-course-of-pd-1-monoclonal-antibody","phase":"phase_3","mechanism":"A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.","indications":["Advanced or metastatic melanoma","Non-small cell lung cancer","Renal cell carcinoma","Hodgkin lymphoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Full course of PD-1blockades","genericName":"Full course of PD-1blockades","slug":"full-course-of-pd-1blockades","phase":"phase_3","mechanism":"PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer","Renal cell carcinoma","Hodgkin lymphoma","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE43dnJrRnphbk9uY0c1Tjl0dk5VVlpYdzAxM3VUSTJlMDRFWTJSei1MTnM5QjhIZU0tb2NMdkhEMEM2N1JIWV9vdkJOQzB1eTVWOUxzaUM0aFdmNHNIV3Mw?oc=5","date":"2024-03-29","type":"pipeline","source":"Nature","summary":"Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer - Nature","headline":"Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}